Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 66, Issue 11, Pages 985-991
Publisher
BMJ
Online
2013-06-26
DOI
10.1136/jclinpath-2012-201375
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome
- (2012) Y-Q Zhang et al. BRITISH JOURNAL OF CANCER
- The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
- (2012) Teeara Berry et al. CANCER CELL
- Development of treatment strategies for advanced neuroblastoma
- (2012) Junichi Hara International Journal of Clinical Oncology
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
- (2012) Rafal Dziadziuszko et al. Journal of Thoracic Oncology
- MET Expression and Amplification in Patients with Localized Gastric Cancer
- (2011) Y. Y. Janjigian et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
- (2011) Andrew S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas
- (2011) Koji Tsuta et al. Journal of Thoracic Oncology
- Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
- (2011) Sohei Yamamoto et al. MODERN PATHOLOGY
- Crizotinib in Anaplastic Large-Cell Lymphoma
- (2011) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
- (2011) S. C. Bresler et al. Science Translational Medicine
- Emerging importance of ALK in neuroblastoma
- (2011) Anna M. Azarova et al. SEMINARS IN CANCER BIOLOGY
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
- (2010) Yoshinari Asaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma
- (2010) P. G. Buckley et al. CLINICAL CANCER RESEARCH
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
- (2009) Hal E Crosswell et al. BMC CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now